Bryxta 300mg Injection
Rx RequiredSalt Composition: Bevacizumab
Expiry Date: 01/2028
Price on Request
Inclusive of all taxes
12ml/Vial
About The Product
Colorectal Cancer
Description
Bryxta 300mg tablet is a targeted drug prescribed by the healthcare professional for the treatment of colorectal cancer in adult men and women. Its active ingredient is Bevacizumab, a monoclonal antibody.
It works by blocking the vascular endothelial growth factor ( VEGF), a protein which stimulate the development of blood cells and the process called angiogenesis. Doctors do not prescribe this medication to adults children under the age of 18 to ensure safety.
Proper medical attention is required while taking the medication as it may cause side effects.
Indication
Colorectal cancer
Common Side Effects
• Headache
• Vision changes
• Confusion
• Severe allergic reactions
• High Blood pressure
• Numbness in hands or feet
• Weakness and lack of energy
• Diarrhea, nausea, vomiting, abdominal pain
• Constipation
• Loss of appetite
Dosage And Duration
- Bryxta 300mg tablet should taken under the strict supervision of a healthcare professional.
- Taking in the wrong way may cause severe side effects.
- Follow the prescribed dosage as recommended and schedule exactly as advised by the doctor.
- Do not chew or crush the medication as it may reduce its effectiveness and interfere with how the medication is absorbed in the body.
Mechanism Of Action
Colorectal cancer is caused by genetic mutations in colon cells, causing them to grow uncontrollably and become cancerous. Bryxta 300 mg tablet contains Bevacizumab, a VEGF inhibitor that blocks vascular endothelial growth factor (VEGF), which tumors use to form new blood vessels.
The medication helps slow tumor growth, reduce the risk of metastasis, and complement other cancer treatments.
Safety Advice
Faqs
Bryxta 300mg Injection show common as well as severe side effects, including- Joint swelling, fatigue, nausea, urinary tract infection, diarrhea and high blood pressure, consult the healthcare provider if the symptoms persist.
References
• McCormack, P. L., & Keam, S.
J. (2008).
Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs, 68(4), 487-506. • Burger, R.
A., Brady, M. F., Bookman, M.
A., Fleming, G. F., Monk, B.
J., Huang, H., ... & Liang, S. X.
(2011). Incorporation of bevaciz • Bakri, S.
J., Snyder, M. R., Reid, J.
M., Pulido, J. S., & Singh, R.
J. (2007).
Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology, 114(5), 855-859. • Keating, G.
M. (2014).
Bevacizumab: a review of its use in advanced cancer. Drugs, 74(16), 1891-1925. • Ferrara, N., Hillan, K.
J., Gerber, H. P., & Novotny, W.
(2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
Nature reviews Drug discovery, 3(5), 391-400.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
